Ellsworth Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
ETC
Ellsworth Advisors's BMY Position: Q2 2026 in Review
Ellsworth Advisors increased its Bristol-Myers Squibb (BMY) stake by 3.2% in Q2 2026, buying an estimated $220K and bringing the position to 125,533 shares worth $7.37M. The position accounts for 1.21% of the portfolio, ranked #29.
Ellsworth Advisors first reported a position in BMY in Q2 2020 and has held it in 16 quarters since. The position peaked at $7.38M in Q1 2026. 808 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Ellsworth Advisors held 125,533 shares of Bristol-Myers Squibb worth $7.37M as of Q2 2026.
- Ellsworth Advisors bought 3,836 Bristol-Myers Squibb shares in Q2 2026, an estimated $220K.
- Bristol-Myers Squibb made up 1.21% of Ellsworth Advisors's portfolio in Q2 2026, its #29 holding.
- Ellsworth Advisors first reported a position in Bristol-Myers Squibb in Q2 2020 and has held it in 16 quarters since.
- Ellsworth Advisors's Bristol-Myers Squibb position peaked at $7.38M in Q1 2026.
- 808 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Ellsworth Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.